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Abstract: In order to evaluate the potential of a technology platform based on hyaluronan copolymers
grafted with propargylated ferulate fluorophores (HA-FA-Pg) in the development of drug delivery
systems, the propargyl groups of HA-FA-Pg derivatives were employed with oleic acid (OA) or stearic
acid (SA) residues across a biocompatible hexa(ethylene glycol) (HEG) spacer. The designed materials
(i.e., HA-FA-HEG-OA or HA-FA-HEG-SA) showed clear-cut aggregation features in an aqueous
environment, as confirmed by dynamic light scattering (DLS) and transmission electron microscopy
(TEM), generating nanoaggregate systems. In fact, HA-FA-HEG-OA and HA-FA-HEG-SA derivatives
showed the property to create self-assembled cytocompatible nanostructured aggregates in water,
thanks to the simultaneous presence of hydrophilic portions in the polymeric backbone, such as
hyaluronic acid, and hydrophobic portions in the side chains. Furthermore, the designed materials
interact with living cells showing a high degree of cytocompatibility. The potential ability of
nanosystems to load pharmacologically active molecules was assessed by the physical entrapment
of olanzapine into both polymeric systems. The drug loading evaluation demonstrated that the
nanoparticles are able to incorporate a good quantity of olanzapine, as well as improve drug solubility,
release profile, and cytocompatibility.
Keywords: hyaluronic acid; ferulic acid; oleic acid; stearic acid; olanzapine; self-assembling
nanocarriers; drug delivery systems
1. Introduction
Hyaluronic acid (HA, hyaluronan) is a glycosaminoglycan, which possesses important functions
in the human body such as the formation of a pericellular coat having a crucial role in the early stages
of cell adhesion [1]. In fact, HA interacts with the cluster of differentiation 44 (CD44) receptor [2,3]
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(a ubiquitous protein expressed in high density in tumor tissues [4]) showing an extracellular
hyaluronan-binding domain.
In our previous studies, a synthetic procedure was developed to functionalize HA with ferulic
acid (FA) residues in order to obtain graft copolymers (i.e., HA-FA derivatives, Figure 1) showing
intriguing gelating and wound healing properties [5,6].
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Figure 1. Design and development of the technology l based on hyaluronan cop lymers grafted
with pro argylated ferulate fluorophores (HA-F Pg).
Subsequently, the grafting procedure was modified by using a ferulate (FA) derivative bearing a
propargyl group, in or er to introduce clickable groups to be employed in click-chemistry coupling
reactions such as copper(I)-catalyzed azide–alkyne 1,3-dipolar cycloaddition (CuAAC) [7–10]. The
procedure was optimized by using low-molecular-weight HA (molecular weight (MW) of about 8.7
kg·mol−1), which provided hyaluronan copolymers grafted with propargylated ferulate fluorophores
(HA-FA-Pg) showing grafting degree values in the range from 10% to 35% [11].
HA-FA-Pg deri atives were employed as the basis of a covalent coating technology with HA. In
particular, an HA-FA-Pg derivative it 2–3 FA residues bearing a propargyl group was successfully
used in the covalent coating of inorganic mag etite nanoparticles [12]. Moreover, an HA-FA-Pg
derivative bearing 4–5 FA residues was used in the covalent coating of a pi-stacked polybenzofulvene
derivative [13–19] to prepare the intriguing orga ic material TCPB (Figure 1) [20].
In TCPB architecture, HA plays the role of the coating agent f r both the polybenzofulvene
cylindrical brush and the gel nanoparticles generated by TCPB a gregation in the water
enviro ment [20,21]. Interestingly, the gel nanoparticles were demonstrated to beh ve as intri uing
carriers, capable of transporting the a ticancer drug doxorubicin to cancer cells by exploiting the
interaction of HA with the CD44 receptor ov rexpressed on the cell surface of tumor tissues [21].
The core of the nanogel systems generated by TCPB is constituted by the hig ly hydr phobic
polybenzofulvene backbone and by the amphiphilic nona(ethylene glycol) ( ) si e chains that were
assumed to form suitable compartments for drug loading, transport, and delivery.
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However, in such architecture, the major potential drawback could be envisaged in the high
hydrophobicity of the covalent backbone of the polybenzofulvene brush. Thus, in order to overcome
this potential drawback, we envisioned the replacement of the covalent synthetic polybenzofulvene
backbone of TCPB with oleic acid (OA), potentially capable of establishing networks in an aqueous
environment by means of non-covalent interactions. These considerations led to the design of the
tetra-component materials HA-FA-NEG-OA (Figure 1), which showed very intriguing features [11].
In particular, HA-FA-NEG-OA derivatives showed the tendency to generate nanostructured
aggregates in water, which were cytocompatible and could be visualized by fluorescence microscopy
techniques by virtue of the AIE (aggregation-induced emission) features of the ferulate luminogen [11].
Moreover, HA-FA-NEG-OA materials are capable of interacting with the phospholipid bilayer of
monolamellar liposomes with an increase in the negative zeta potential without alterations in the
liposome dimensions and the fluorogenic properties of the ferulate fluorophore [11]. On the basis of
these promising results, HA-FA-NEG-OA materials could not only find applications in the coating of
hydrophobic surfaces, but also in the formation of micellar systems potentially useful in the design of
drug delivery systems [22–24].
Because of the multi-component architecture, the features of these materials could be modulated
by the suitable variation of each component: (a) the polysaccharide chain, (b) the fluorophore, (c) the
spacer, and (d) the fatty acid.
In the present paper, we describe the effects of the modification of two components of the
previously described HA-FA-NEG-OA materials, namely, the spacer and the fatty acid. In particular,
the nona(ethylene glycol) spacer was replaced with a more readily available hexa(ethylene glycol)
(HEG) spacer, and the monounsaturated oleic acid (OA) residues were replaced with saturated stearic
acid (SA) residues, thus producing HA-FA-HEG-OA and HA-FA-HEG-SA materials (Figure 1). The
designed materials showed clear-cut aggregation features in an aqueous environment, highlighted by
dynamic light scattering (DLS) and transmission electron microscopy (TEM) analysis, as well as the
potential to act as cytocompatible nanocarriers for active molecules. In this study, olanzapine (OZ) was
tested as a model drug [25,26].
2. Materials and Methods
The reagents and solvents were obtained from Sigma-Aldrich and were used as received.
Olanzapine (OZ, MW 312.43 g/mol) was purchased from Merck KGaA (Darmstadt, Germany). Ethanol,
Dulbecco’s phosphate-buffered saline (DPBS), anhydrous dimethyl sulfoxide (DMSO), sodium chloride,
and sodium hydroxide were obtained from Merck KGaA (Darmstadt, Germany). The water used was
produced with Milli-Q ® (Millipore Corporation, Billerica, MA, USA). Merck silica gel 60 (230–400
mesh) was employed for column chromatography, and Merck thin layer chromatography (TLC)
aluminum sheets (silica gel 60 F254) were employed for TLC. NMR spectra were obtained with a Bruker
DRX-400 AVANCE or a Bruker Avance III 500 spectrometer in the indicated solvents. The chemical
shifts are referenced to the solvent signal (CDCl3: δ(1H) = 7.26 ppm, δ(13C) = 77.0 ppm) or to the signal
of a trace acetone for solutions in D2O (δ(1H) = 2.22 ppm, δ(13C)CH3 = 30.9 ppm). Chemical shifts (δ)
are reported in ppm, and the H–H coupling constants (J) are reported in Hz. An Agilent 1100 LC/MSD
running with an electrospray source was used in mass spectrometry measurements. The intermediate
α-azido-ω-amino hexa(ethylene glycol) 3 was synthesized as previously reported in Reference [27].
2.1. Synthesis and Characterization
N-(17-Azido-3,6,9,12,15-pentaoxaheptadecyl)oleamide (4a)
A mixture of oleic acid (1a, 0.34 g, 1.20 mmol) and1,1′-carbonyldiimidazole (CDI) (0.20 g,
1.23 mmol) in dry tetrahydrofuran (THF) (5.0 mL) was refluxed for 2 h, and then a solution
O-(2-aminoethyl)-O′-(2-azidoethyl)tetraethylene glycol (3, 0.40 g, 1.31 mmol) in dry THF (5.0 mL) was
added. The resulting mixture was stirred overnight at room temperature and then concentrated under
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reduced pressure. The resulting oily residue was purified by flash chromatography with ethyl acetate
to obtain 4a as a pale-yellow oil (0.65 g, yield 95%). 1H-NMR (400 MHz, CDCl3): 0.87 (t, J = 6.6, 3H),
1.24–1.31 (20H), 1.62 (m, 2H), 1.92–2.05 (4H), 2.16 (t, J = 7.6, 2H), 3.37 (t, J = 5.1, 2H), 3.44 (q, J = 5.1, 2H),
3.54 (t, J = 5.1, 2H), 3.59–3.74 (18H), 5.24–5.43 (2H), 6.05 (br s, 1H). MS (ESI): m/z 593.2 (M + Na+).
N-(17-Azido-3,6,9,12,15-pentaoxaheptadecyl)stearamide (4b)
A mixture of stearic acid (1b, 0.18 g, 0.63 mmol) and CDI (0.10 g, 0.62 mmol) in dry THF (10 mL)
was refluxed for 2 h, and then a solution of O-(2-aminoethyl)-O′-(2-azidoethyl)tetraethylene glycol
(3, 0.20 g, 0.65 mmol) in dry THF (5.0 mL) was added. The resulting mixture was stirred overnight
at room temperature and then concentrated under reduced pressure. The resulting oily residue was
purified by flash chromatography with petroleum ether/ethyl acetate (1:1) to obtain 4b as a white solid
(0.33 g, yield 93%, melting point (mp) 48–50 ◦C). 1H-NMR (400 MHz, CDCl3): 0.87 (t, J = 6.7, 3H),
1.17–1.38 (28H), 1.60 (m, 2H), 2.15 (t, J = 7.6, 2H), 3.37 (t, J = 5.1, 2H), 3.43 (q, J = 5.3, 2H), 3.54 (t, J = 5.0,
2H), 3.58–3.72 (18H), 6.02 (br s, 1H). MS (ESI): m/z 595.2 (M + Na+).
Preparation of HA-FA-HEG-OA
A round-bottom 10-mL flask was charged, under an inert atmosphere, with tert-butanol (2.0
mL), H2O (2.0 mL), and a solution of copper sulfate pentahydrate (12.5 mg, 0.050 mmol in 0.50 mL of
water). Subsequently, a 1 M water solution of sodium ascorbate (0.50 mL) was added. A portion of the
resulting catalyst solution (1.0 mL) was promptly used in the subsequent reaction.
To a mixture of HA-FA-Pg graft copolymer bearing a mean distribution of 4–5 propargyl derivatives
for each macromolecule (200 mg, synthetic procedure reported in Reference [11]) in 5.0 mL of water
containing 4a (60 mg, 0.105 mmol), 1.0 mL of the catalyst solution was added, and the resulting mixture
was stirred at room temperature for 1 h and then treated with QUADRASIL MP (200 mg). After
filtration, the resulting mixture was concentrated under reduced pressure. The solid residue was
purified by washing with acetone to obtain pure HA-FA-HEG-OA as a light-brown solid (218 mg).
1H-NMR (500 MHz, D2O): the spectrum is depicted in Figure 3c; 13C-NMR (125 MHz, D2O), selected
signals: 14.6 (18”), 23.2 (17”, Et), 26.4 (3”), 27.8 (8”, 11”), 29–32 (4”–7”, 12”–15”), 32.5 (16”), 36.6 (2”),
39.6 (H), 50.8 (E), 69–72 (F,G,X,Y), 130.0 and 130.4 (9”,10”), 175.6 (1”). For the spectrum and the atom
numbering, compare Figure 4d.
Preparation of HA-FA-HEG-SA
Under an inert atmosphere, a round-bottom 10-mL flask was charged with tert-butanol (2.0 mL),
H2O (2.0 mL), and a solution of copper sulfate pentahydrate (12.5 mg, 0.050 mmol in 0.50 mL of
water). Subsequently, a 1 M water solution of sodium ascorbate (0.50 mL) was added. A portion of the
resulting catalyst solution (1.0 mL) was promptly used in the subsequent reaction.
To a mixture of HA-FA-Pg graft copolymer bearing a mean distribution of 4–5 propargyl derivatives
for each macromolecule (200 mg, synthetic procedure reported in Reference [11]) in water (5.0 mL)
containing 4b (62 mg, 0.108 mmol), 1.0 mL of the catalyst solution was added, and the resulting mixture
was stirred at room temperature for 1 h and then treated with QUADRASIL MP (200 mg). After
filtration, the resulting mixture was concentrated under reduced pressure. The solid residue was
purified by washing with acetone to obtain HA-FA-HEG-SA as a light-brown solid (230 mg). 1H-NMR
(500 MHz, D2O): the spectrum is depicted in Figure 3d; 13C-NMR (125 MHz, D2O), selected signals:
14.6 (18”), 23.2 (17”,Et), 26.4 (3”), 29–32 (4”–15”), 32.6 (16”), 36.6 (2”), 39.7 (H), 69–72 (F,G,X,Y), 175.6
(1”). For the spectrum and the atom numbering, compare Figure 4c.
(E)-Methyl 3-[3-methoxy-4-[[1-[(Z)-19-oxo-3,6,9,12,15-pentaoxa-18-azahexatriacont-27-en-1-yl]-1H-
1,2,3-triazol-4-yl]methoxy]phenyl]acrylate (FE-HEG-OA)
Under an inert atmosphere, a round-bottom 10-mL flask was charged with tert-butanol (2.0 mL),
H2O (2.0 mL), and a solution of copper sulfate pentahydrate (12.5 mg, 0.050 mmol in 0.50 mL of water).
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Then, a 1 M water solution of sodium ascorbate (0.50 mL) was added. A portion of the resulting
catalyst solution (1.0 mL) was promptly used in the subsequent reaction. A mixture of 4a (250 mg, 0.44
mmol) and 5 [20] (110 mg, 0.45 mmol) in 4.0 mL of tert-butanol and water (2.0 mL) was treated with
the catalyst solution (2.7 mL), and the reaction mixture was stirred overnight at room temperature and
then concentrated under reduced pressure. Purification of the residue by flash chromatography with
ethyl acetate/methanol (9:1) as the eluent afforded FE-HEG-OA as a pale-yellow oil (337 mg, yield
92%). 1H-NMR (500 MHz, CDCl3): 0.88 (t, J = 6.9, 3H; 18”), 1.2–1.35 (20H; 4”–7”,12”–17”), 1.62 (m, 2H;
3”), 2.00 (4H; 8”,11”), 2.16 (t, J = 7.6, 2H; 2”), 3.43 (q, J = 5.3, 2H; H), 3.54 (t, J = 5.1, 2H; G), 3.55–3.65
(16H; X,Y), 3.80 (s, 3H; A”), 3.87 (t, J = 5.0, 2H; F), 3.89 (s, 3H; A), 4.53 (t, J = 5.0, 2H; E), 5.3–5.35 (4H;
9”,10”,B), 6.05 (br, 1H; NH), 6.31 (d, J = 16.0, 1H; 2), 7.05–7.10 (3H; 2′,5′,6′), 7.62 (d, J = 16.0, 1H; 3),
7.83 (s, 1H; D). 13C NMR (125 MHz, CDCl3): 14.1 (18”), 22.7 (17”), 25.7 (3”), 27.2 (8”,11”), 29.2–29.7
(4”–7”,12”–15”), 31.9 (16”), 36.7 (2”), 39.1 (H), 50.4 (E), 51.6 (A’), 55.9 (A), 63.0 (B), 69.4 (F), 70.0–70.5
(F,G,X,Y), 110.3 (2′), 113.7 (5′), 115.9 (2), 122.4 (6′), 124.3 (D), 128.1 (1′), 129.7 and 130.0 (9”,10”), 143.5
(C), 144.6 (3), 149.7, and 149.8 (3′,4′), 167.6 (1), 173.2 (1”). For spectra and the atom numbering, compare
Figures 3e and 4e. MS (ESI): m/z 839.5 (M + Na+).
(E)-3-[3-Methoxy-4-[[1-[(Z)-19-oxo-3,6,9,12,15-pentaoxa-18-azahexatriacont-27-en-1-yl]-1H-1,2,3-triazol-
4-yl]methoxy]phenyl]acrylic acid (FA-HEG-OA)
A mixture of FE-HEG-OA (0.33 g, 0.40 mmol) in ethanol (7.5 mL) containing a 2 N water solution
of NaOH (4.7 mL) was refluxed for 2 h. The reaction mixture was then cooled at 0 ◦C, acidified with 3
N HCl, and concentrated under reduced pressure. Purification of the residue by flash chromatography
with dichloromethane/methanol (9:1) gave acid FA-HEG-OA as a white solid (0.28 g, yield 87%, mp
67–69 ◦C). 1H-NMR (500 MHz, CDCl3): 0.88 (t, J = 6.9, 3H; 18”), 1.2–1.35 (20H; 4”–7”,12”–17”), 1.62 (m,
2H; 3”), 2.00 (4H; 8”,11”), 2.17 (t, J = 7.6, 2H; 2”), 3.44 (q, J = 5.3, 2H; H), 3.5–3.65 (18H; G,X,Y), 3.86 (t, J
= 5.0, 2H; F), 3.90 (s, 3H; A), 4.53 (t, J = 5.0, 2H; E), 5.3–5.4 (4H; 9”,10”,B), 6.12 (br, 1H; NH), 6.31 (d, J =
16.0, 1H; 2), 7.05–7.10 (3H; 2′,5′,6′), 7.68 (d, J = 16.0, 1H; 3), 7.81 (s, 1H; D), 10.60 (br, 1H; COOH). 13C
NMR (125 MHz, CDCl3): 14.1 (18”), 22.6 (17”), 25.7 (3”), 27.2 (8”,11”), 29.1–29.7 (4”–7”,12”–15”), 31.9
(16”), 36.7 (2”), 39.1 (H), 50.4 (E), 55.9 (A), 62.9 (B), 69.4 (F), 70.0–70.5 (F,G,X,Y), 110.4 (2′), 113.7 (5′),
115.6 (2), 122.7 (6′), 124.3 (D), 127.8 (1′), 129.7 and 130.0 (9”,10”), 143.5 (C), 146.2 (3), 149.7, and 150.0
(3′,4′), 170.9 (1), 173.4 (1”). For spectra and the atom numbering, compare Figure 2. MS (ESI): m/z 825.5
(M + Na+).
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Figure 2. 1H- and 13C-NMR spectra of model compound FA-HEG-OA in CDCl3.
2.2. Particle Size Analysis and Zeta Potential
The size analysis, zeta potential, and polydispersity index of the nanoparticles (NPs) were
determined using Malvern Ze asizer Nano ZS nstrument, fitted with a 532-nm laser at a fixed
scattering angle of 90◦. The samples were a alyzed before and after drug loadi g. Each sample was
suitably diluted and filtered before the analysis an placed i a disposable sizi micro cuvette.
2.3. Critical Aggregation Concentration
Critical aggregation concentration (CAC) evaluation was carried out in water and in DPBS by
means of the pyrene fluorescence assay. At the beginning, a solution of pyrene in acetone was prepared
(6.0 × 10−5 M); then, aliquots of 20 µL of this solution were placed in vials and left to evaporate for 30
min in orbital shaker at 37 ◦C in order to remove the acetone. Afterward, 2 mL of the polymer aqueous
dispersions were added to the pyrene solid residue. Polymer concentrations were included in a range
from 10 to 0.0005 mg/mL. In this way, the final concentration of pyrene in each sample was, thus, equal
to 6.0 × 10−7 M. The mixtures were kept at 37 ◦C for 1 h under continuous agitation, inside an orbital
shaker, in order to balance the pyrene with the micelles. The pyrene excitation and emission spectra
were recorded at 25 ◦C at an excitation wavelength of 333 nm and an emission wavelength of 373 nm.
2.4. Transmission Electron Microscopy (TEM) Analysis
In order to chara terize m rphology and size of NPs, a TEM analysis was carried out. Samples
were visualized using an electronic microscope JEOL JEM-2100 at 100 KV, and Digital Micrograph
Gatan (Gatan, Inc., Pleasanton, CA, USA) was used as the software. Samples (1.0 mg) were solubilized
in water (1.0 mL). A drop of each sample was placed in a carbon-coated grid and dried overnight
before analysis.
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2.5. Rheological Analysis
Firstly, 2%w/vHA-FA-HEG-SA and HA (MW 8700 g·mol−1) solutions were prepared in bi-distilled
water. Flow curves were recorded using an HR-2 Hybrid-Rheometer (TA-Instruments, Leatherhead,
United Kingdom) with a cone-plate measuring device 40 mm in diameter, employing a gap size of 0.1
mm. The temperature was maintained at 25 ◦C. The dynamic viscosity η under a controlled shear rate
ranging from 1 to 100 s−1 was measured [28].
2.6. Preparation of Self-Assembling Nanoparticles
Olanzapine (OZ, MW 312.43 g/mol) was purchased from Merck KGaA (Darmstadt, Germany).
Ethanol, Dulbecco’s phosphate-buffered saline (DPBS), anhydrous dimethyl sulfoxide (DMSO), sodium
chloride, and sodium hydroxide were obtained from Merck KGaA (Darmstadt, Germany). The water
used was produced with Milli-Q ® (Millipore Corporation, Billerica, MA, USA).
Aliquots of HA-FA-HEG-OA (30 mg) and HA-FA-HEG-SA (30 mg) were dissolved in 3.0 mL of
Milli-Q water and left, under vigorous stirring, at room temperature overnight. The day after, OZ
(15 mg) was added to polymer dispersions, to get a drug concentration of 5 mg/mL, and the mixture
was left under vigorous stirring, at room temperature overnight. After this time, the dispersions were
centrifuged at 8000 rpm and 25 ◦C for 5 min to remove the drug, which was not incorporated in the
self-assembling nanoparticles (NPs). Supernatant was recovered and then dried by freeze-drying,
thereby obtaining a spongy solid.
2.7. Drug Content and Encapsulation Efficiency
The drug content in the NP was determined by dissolving 2.0 mg of the obtained dried products
in 2.0 mL of anhydrous DMSO. Absorbance of the solutions was then measured spectrophotometrically
at 276 nm after appropriate dilution 1:10 in anhydrous DMSO, and the drug content in the NP was
determined. Drug loading (DL) in the NP was calculated by using the calibration curve, built in a
range between 0.05 and 0.001 mg/mL, as follows:
DL (%) = A/B × 100,
where A is the drug content in the NP, and B is the weight of NP. The results were confirmed taking
into consideration the polymer’s interference in the analysis.
2.8. Drug Release Studies
The release of OZ from HA-FA-HEG-OA and HA-FA-HEG-SA NP was evaluated using the
dialysis bag diffusion technique. The release studies were performed in Dulbecco’s phosphate-buffered
saline (DPBS) (pH 7.4) mimicking plasma compartment pH conditions, with 3% (v/v) Tween-80 to
create a perfect sink condition, since OZ has limited solubility in the buffer. The aqueous NP dispersion
equivalent to 0.7 mg of OZ was placed into a dialysis bag (cut-off 3.5–5 kDa; Spectra por, Flot-A-Lyzer
G2 Dialysis Device). The dialysis bag was immersed in the acceptor compartment containing 50 mL of
DPBS pH 7.4 plus 3% v/v Tween-80, and incubated under continuous stirring (100 rpm) and maintained
at 37 ◦C in an orbital shaker incubator for 30 h. The acceptor compartment was covered to prevent the
evaporation. At regular time intervals, specific volumes of the external medium were withdrawn, and
the same volume was replaced by fresh buffer. The withdrawn samples were centrifuged and then
freeze-dried. The solid residues were dissolved in DMSO and analyzed spectrophotometrically at 276
nm. The amount of released OZ was determined by using a calibration curve, built in a range between
0.05 and 0.001 mg/mL. The released OZ was determined as a function of incubation time, and it is
reported as the weight percentage of the total amount of drug loaded into the polymer aggregates. The
dilution procedure was considered in the correction of the data.
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2.9. Cytotoxicity Assay
Cell viability was assessed on human bronchial epithelial cells (16HBE) by the tetrazolium salt
(MTS) assay. Cells were grown in Dulbecco’s modified Eagle’s medium (DMEM) with 10% FBS (fetal
bovine serum) and 1% penicillin/streptomycin (100 U·mL−1 penicillin and 100 µg·mL−1 streptomycin),
at 37 ◦C in a 5% CO2 humidified atmosphere after seeding in a 96-well plate at a density of 2 ×
104 cells per well. Different amounts of nanosystems (i.e., empty and OZ-loaded HA-FA-HEG-OA
and HA-FA-HEG-SA) and free OZ as control were weighed in order to obtain drug concentrations
corresponding to 350 µM, 200 µM, 100 µM, and 50 µM. The empty and OZ-loaded systems were
dispersed in DMEM, while OZ was dissolved in DMSO because of the low drug solubility in water.
Aliquots of the sample dispersions (200 µL) were added to the cells and incubated for 24 h. After
incubation, in each well, the medium was replaced with 100 µL of fresh DMEM and 20 µL of MTS
(3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) reagent
solution. Plates were incubated at 37 ◦C in a 5% CO2 humidified atmosphere for 1 h. Absorbance
was measured by a multi-well plate reader (Eppendorf AF 2200) at 490 nm. All the experiments were
performed in triplicate, and average values were calculated. The equation, (Abs490 treated cells/Abs490
control cells) × 100, was used to calculate the relative cell viability (percentage) as an average of three
values. A positive control was obtained with untreated cells.
2.10. Statistical Analysis
A one-way analysis of variance (ANOVA) was applied to compare different samples. Data were
considered statistically significant with a value of p < 0.05, and differences between groups were
compared using the Bonferroni t-test. Each test was developed in triplicate.
3. Results and Discussion
3.1. Synthesis of HA-FA-HEG-OA and HA-FA-HEG-SAMaterials
HA-FA-HEG-OA and HA-FA-HEG-SA derivatives were prepared from the previously
published HA-FA-Pg derivative, bearing a mean distribution of 4–5 propargyl derivatives for each
macromolecule [11] by CuAAC coupling [29] with the suitable α-azido-ω-fatty amide hexa(ethylene
glycol) (azido-HEG-OA, 4a or azido-HEG-SA, 4b) as shown in Scheme 1.
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(ii) TEA, THF; (iii) CuSO4, sodium ascorbate, tert-BuOH, H2O. Substituents: R = H or C2H5; R’ =
C17H33 (1a, 2a, 4a, HA-FA-HEG-OA) or C17H35 (1b, 2b, 4b, HA-FA-HEG-SA).
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In particular, the appropriate fatty acid (OA, 1a or SA, 1b) was activated with
1,1′-carbonyldiimidazole (CDI) in refluxing THF to obtain the corresponding imidazolide (2a,b),
which was promptly reacted with α-azido-ω-amino hexa(ethylene glycol) (3) to obtain the required
azido-HEG-OA (4a) or azido-HEG-SA (4b). The CuAAC coupling was performed under very mild
conditions with the copper(I) catalyst being generated in situ with CuSO4/sodium ascorbate. Moreover,
the coupling reaction was carried out by using HA-FA-Pg samples obtained from low-molecular-weight
HA (MW about 8.7 kg·mol−1) and showing a degree of grafting around 20%, corresponding to four
propargyl groups per HA macromolecule in order to prepare materials bearing about four fatty-acid
side chains pending from the HA backbone [11].
The intermediate α-azido-ω-amino hexa(ethylene glycol) [27] (3) was synthesized as described in
Scheme 2 and previously reported in Reference [27].
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Finally, compound FA-HEG-OA and its methyl ester precursor 8 were synthesized from ferulate
derivative 9 [11] and compound 4a as described in Scheme 3 in order to be used as model compounds.
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3.2. Structure of HA-FA-HEG-OA and HA-FA-HEG-SAMaterials
The structure of HA-FA-HEG-OA and HA-FA-HEG-SA derivatives was studied by 1H- and
13C-NMR spectroscopy in D2O as the solvent (Figures 3 and 4).
In a first step, the assignment of the 1H- and 13C-NMR spectra of HA-FA-Pg was re-investigated
in order to evaluate previous assignments [11,20]. In particular, we focused on the signals of the
propargyl group, which are considered diagnostic signals for evaluating the functionalization of the
HA-FA-Pg copolymer. Combing one-dimensional (1D) and two-dimensional (2D) NMR methods, the
signals of propargyl protons B and D, as well as of carbons B, C, and D, can be unequivocally assigned
(Figures 3b and 4b)
The intensity of the proton signals allows monitoring their conversion after the CuAAC click
reaction. Thus, in order to ascertain the effectiveness of the CuAAC coupling reaction producing
HA-FA-HEG-OA and HA-FA-HEG-SA derivatives, the 1H- and 13C-NMR spectra of these materials
were compared with the corresponding spectra of HA and HA-FA-Pg (Figures 3 and 4).
The conversion of the alkyne moiety of HA-FA-Pg into the triazole one of HA-FA-HEG-OA and
HA-FA-HEG-SA, indicative of a successful CuAAC coupling reaction, was proven by the disappearance
of the signal of acetylene proton D at 2.98 ppm observed in the 1H-NMR spectrum of HA-FA-Pg
(Figure 3b) and the appearance of a new peak at around 8 ppm in the spectra of HA-FA-HEG-OA and
HA-FA-HEG-SA (Figure 3c,d). Analogously, in the 13C-NMR spectra (Figure 4), the alkyne signal C at
78.5 ppm disappeared. This observation was first evidence of the covalent insertion of components
HEG-OA or HEG-SA in the new materials. Moreover, a significant line broadening was observed for
the signals assigned to the aromatic and acrylic protons of the FA moiety.
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(d) derivatives measured in D2O and FE-HEG-OA (e) measured in CDCl3 with those obtained from
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units with R = C2H5.
Pharmaceutics 2019, 11, 675 11 of 20
Pharmaceutics 2019, 11, x 11 of 20 
 
 
Figure 4. Comparison of 13C-NMR spectra of  HA-FA-HEG-SA (c) and HA-FA-HEG-OA (d) 
derivatives measured in D2O and FE-HEG-OA (e) measured in CDCl3 with those obtained from 
starting HA-FA-Pg (b) and HA (a) samples in D2O. In the spectrum of HA, “Et” labels indicate the 
signals of ethyl groups of the monomeric units with R = C2H5. 
Owing to their complex structures, the 1H-NMR spectra of HA-FA-HEG-OA and 
HA-FA-HEG-SA (Figure 3) were composed by a hard-to-assign set of broad and partially 
overlapped signals of the different substructures, representing the hyaluronan backbone, FA triazole 
moiety, and PEG fatty acid functional group. However, the 13C-NMR spectra allowed a closer view 
of the chemical structures. In this context, two model substances, FE-HEG-OA (Figure 3e,4e) and 
FE-HEG-SA (Figure 2), were synthesized and characterized in detail by 1H- and 13C-NMR 
spectroscopy. As obvious from the comparison of 13C-NMR spectra in Figure 4, in addition to the 
dominating signals of the HA backbone, both the HEG signals in the 72–69 ppm region and the alky 
group signals (40 – 25 ppm, CH3 group at 14.6 ppm) appeared. For the OA derivative, the olefinic 
carbons resulted in two signals at 130.4 and 130.0 ppm. 
Unlike the parent HA-FA-Pg, the signals of the aromatic carbon atoms of the ferulate–triazole 
structure were almost not detectable. In an attempt to explain this result, we assumed that the FA 
moiety suffered from reduced mobility, maybe due to poor solvation in D2O producing a 
pronounced line broadening as already observed in the 1H-NMR spectra in Figure 3. Here, one has 
to recall the disappearance of propargyl signals and the persistence of the signal assigned to the 
ferulate methoxy (at about 55.6 ppm). Consequently, by comparison of the NMR spectra of the new 
copolymer materials with those of the starting materials and synthesized model molecules, we 
successfully assigned all detectable signals of the complex spectra obtained for HA-FA-HEG-OA 
and HA-FA-HEG-SA. 
  
Figure 4. o arison of 13C- spectra of HA-F -HEG-SA (c) and HA-FA-HEG-OA (d) derivatives
measured in D2O and FE-HEG-OA (e) measured in CDCl3 with those obtained from starting HA-FA-Pg
(b) a d (a) samples in D2O. In the spectrum of HA, “Et” labels indicate he signals of ethyl groups
of the monomeric units with R = C2H5.
ing to their complex structures, the 1H-NMR spectra of HA-FA-HEG-O and HA-FA-HEG-SA
(Figure 3) were composed by a hard-to-assign set of broad and partially overlapped sign ls of the
different substructures, repr s ting the hyaluronan backbone, FA triazole moiety, and PEG fatty acid
functional group. However, the 13C-NMR spectra allowed a closer view of the chemical structures.
In this context, two model substances, FE-HEG-OA (Figures 3e and 4e) and FE-HEG-SA (Figure 2),
were synthesized and characterized in detail by 1H- and 13C-NMR spectroscopy. As obvious from the
comparison of 13C-NMR spectra in Figure 4, in addition to the dominating signals of the HA backbone,
both the HEG signals in the 72–69 ppm region and the alky group signals (40 – 25 ppm, CH3 group at
14.6 ppm) appeared. For the OA derivative, the olefinic carbons resulted in two signals at 130.4 and
130.0 ppm.
Unlike the parent HA-FA-Pg, the signals of the aromatic carbon atoms of the ferulate–triazole
structure were almost not detectable. In an attempt to explain this result, we assumed that the FA
moiety suffered from reduced mobility, maybe due to poor solvation in D2O producing a pronounced
line broadening as already observed in the 1H-NMR spectra in Figure 3. Here, one has to recall the
disappearance of propargyl signals and the p rsistence of the ignal assigned to the ferulate methoxy
(at about 55.6 ppm). Consequently, by comparison of the NMR spectra of the new copolymer materials
with those of the starting ma erial a d ynt sized model molecules, we successfully assigned all
detectable signals of the complex spectra obtained for HA-FA-HEG-OA and HA-FA-HEG-SA.
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3.3. Self-Assembling Properties
HA-FA-HEG-OA and HA-FA-HEG-SA were designed to be biocompatible and partially
hydrophilic polymers showing clear-cut aggregation features in an aqueous environment. Thanks to
their partially amphiphilic features, they are potentially capable of forming self-assembled nanoparticles
in water dispersions and loading lipophilic drugs such as olanzapine, the solubility of which is rather
negligible in physiological fluids. Moreover, the hydrophilic portion of the copolymer, which we
assumed to be exposed on the surface of the nanosystems, can be used to provide the nanoparticles
with stealth properties for longer circulation times.
In particular, HA-FA-HEG-OA and HA-FA-HEG-SA derivatives showed a tendency to create
cytocompatible nanostructured aggregates in water, owing to the simultaneous presence of hydrophilic
portions in the polymeric chain (i.e., hyaluronic acid, an essential component of connective tissues in
humans that plays an essential role in the early stages of cell adhesion) and oleic or stearic hydrophobic
portions. The resulting features of the polymeric nanocarriers, such as surface charge, dimensions,
balance between hydrophilic and hydrophobic parts, and biocompatibility, confirmed the possibility of
using these materials as drug delivery systems.
Polymers were simply dispersed in Milli-Q water in a concentration of 0.5 mg/mL and left to shake
alternating with sonication cycles in order to unpack the macromolecules and favor dissolution. The
systems were left to agitate overnight and then analyzed by DLS after filtration in order to evaluate both
the presence of dispersed aggregates and the zeta potential of the particulate matter. The results shown
in Table 1 confirmed the ability of HA-FA-HEG-OA and HA-FA-HEG-SA derivatives to self-assemble
into NPs upon dispersion in water. However, DLS curves (Figure 5) revealed the presence of two
heterogeneous populations: one showing a small mean diameter (below 20 nm) that was assumed to
be constituted by small aggregates of a few macromolecules, and a second population with greater
dimensions constituted by a large number of macromolecules.
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Table 1. Size distribution and zeta (Z) potential values of empty systems.
Samples Size (nm) PDI Z-potential (mV)
HA-FA-HEG-OA 291 0.424 −47
HA-FA-HEG-SA 364 0.442 −35
Moreover, the negative surface charge (in the range −35 to −47 mV) shown by both systems
represents a stabilizing factor owing to repulsion between NPs, preventing their aggregation.
In order to evaluate the potential critical aggregation concentration (CAC) of polymers in aqueous
media, pyrene was used as the fluorescent hydrophobic probe. The high hydrophobicity of the probe
should allow us to predict the ability of the system to internalize active molecules. This method is
based on the difference in pyrene fluorescence when the probe is situated in a water solution or in
the hydrophobic nucleus of micelles [30]. In particular, both the I1/I3 ratio obtained from the pyrene
emission spectra and the I338/I332 ratio obtained from the pyrene excitation spectra, measured at 25 ◦C,
were plotted versus the logarithm of the copolymer concentration. The obtained curves were used
for the evaluation of the critical aggregation concentration (CAC) identifiable with the intersection
of the tangent to the curve at the inflection with the horizontal tangent through the points at lower
concentrations [31].
As can be seen in the graph shown in Figure 6A, for the HA-FA-HEG-OA derivative, there was not a
sufficiently significant change in the emission and excitation spectra to justify a concentration-dependent
aggregation phenomenon. However, at the concentration of 0.5 mg/mL, DLS analysis (Figure 6B)
showed the presence of colloidal particles with a size of 378 nm, which stabilized to the size of 270 nm
at increasing concentrations between 1 and 10 mg/mL.
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Figure 6. I1(373)/I3(3 intensity ratios obtained from pyrene emission spectra (blue curve) and I338/I332
intensity ratios obtained from pyrene excitation spectra (orange curve) for HA-FA-HEG-OA derivative
water dispersions (A) or HA-FA-HEG-SA derivative water dispersions (C) at 25 ◦C, in the concentration
range of 0.0001–10 mg/mL; size distribution values of HA-FA-HEG-OA (B) or HA-FA-HEG-SA (D) in
the same conditions.
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Also, in the case of the HA-FA-HEG-SA derivative (Figure 6C), we were unable to obtain a
characteristic CAC value, but the results of DLS analysis in the concentration range between 0.5 and 10
mg/mL suggested the formation of colloidal particles of increasing size from 363 to 569 nm.
The results suggested that the materials do not form so-called micelles, but rather stable
self-assembled nanoparticles.
TEM observations, reported in Figure 7, showed that HA-FA-HEG-OA (Figure 7A,B) and
HA-FA-HEG-SA (Figure 7C,D) nano-aggregates appeared as spherical objects, showing dimensions
slightly smaller than those obtained by DLS measurements, due to the shrinkage of nano-aggregates
upon dehydration. In line with the DLS results, TEM analysis showed the contemporary presence of
small objects (diameter around 20 nm) and larger nano-aggregates.
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Figure 7. Representative transmission electron micrograph of HA-FA-HEG-OA (A,B) and
HA-FA-HEG-SA (C,D) nanoparticles.
Self-assembling properties of the polymers were also investigated by evaluating the rheological
behavior of HA-FA-HEG-SA as a model sample. The viscosity trend of HA-FA-HEG-SA vs. shear
rate is depicted in Figure 8 and compared with native HA. Both solutions exhibited a shear thinning
behavior, since their viscosities decreased with the shear rate increasing. Specifically, HA-FA-HEG-SA
viscosity decreased from 38 ± 3 mPa·s to 0.13 ± 0.01 mPa·s in the shear rate range of 1–100 s−1, whereas
native HA viscosity decreased from 14 ± 2 mPa·s to 1.1 ± 0.1 mPa·s in the same range. The obtained
results confirmed the capability of functionalized HA to self-assemble into aggregate structures, whose
formation was reflected in the doubled viscosity of the solution in comparison with bare HA.
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3.4. Olanzapine Loading and Release
Due to the potential ability of the nanosystems to load pharmacologically active molecules,
olanzapine [32] was selected as a model drug.
OZ is an antip ychotic agent contained in different pharmaceutical formulations as a free base or
hydrochloride salt. It is used for the tre tment of central nervous system disorders and is available as
coate tablets for oral administration. Recently, the injectable form for intramu cular use of 10 mg was
intr duced for the emergency treatme t of psychomotor agitation in manic crises and schiz phrenic
patients. OZ shows highly permeability to biological membranes; however, on the other hand, it has
very low solubility i water, which limits its bioavailabili y [25].
In or er to increase the bioavailability and reduce its cytotoxic effects, olanzapine was physically
adsorbed into b th polym ric systems reported above. After incorporation, the sy tems were purified
by centrifugati n and filtration in ord to remove non-incorporated drug.
Subsequent analysis by DLS showed some modifications of the physical parameters upon drug
incorporation, with a consequent lowering of size and the zeta potential with resp ct to the empty
nanosystems (Table 2). Definitive y, the calculated drug loading values demonstrated that the NPs
are capable of incorporating a good quantity of OZ. Subsequently, re ea e studie were carried out to
evaluate the ability of systems t release he incorporated drug.
Table 2. Size distribution, Z-potential values, and drug loading of drug-loaded systems.
Samples Size (nm) PDI Z-Potential (mV) Drug Loading (%)
HA-FA-HEG-OA-OZ 234 0.352 −31.1 14.0
HA-FA-HEG-SA-OZ 178 0.260 −24.7 14.2
e rele se r files f -l e ( i re ) s est t t - - -
- - - re tes re le t rele se t e l e cti e lec les s l i e i
c tr lle . e ss ti ic t e rele se st ies ere se s s fficie tl il te
s l ti , able to mimic the don r compartment, where drug solubility does n t limit the drug release.
However, this situation is difficult to meet with poorly water-soluble drug formulations, as a very large
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volume of release medium is required with respect to the formulation, making it a challenge to measure
the drug concentration accurately [33]. Thus, the low solubility of olanzapine in water required
experimental techniques capable of increasing its solubility (in this case, the role of nanoparticles was
to increase the solubilization of the drug). In order to alleviate this difficulty, the sampled solution
compartment was enriched with a surfactant (i.e., Tween-80 at 3%) with the purpose of increasing the
drug solubility. The results shown in the graph of Figure 9 demonstrate the ability of the polymeric
systems to improve the release profile of the loaded drug in a defined time as compared to the release
profile of the drug alone. In particular, the release of OZ loaded into nanosystems was constant in the
first 10 h with a release of about 50% of the encapsulated drug; after 10 h, the release was slower and
almost complete (ca. 80%) after 30 h of incubation. By contrast, the release profile of the free drug
showed only a 30% release within 30 h.
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3.5. In Vitro Biological Evaluations
In order to evaluate the possibility of using HA-FA-HEG-OA and HA-FA-HEG-SA NP as drug
release systems in vivo, preliminary biological tests were carried out using the MTS assay [34]. The
cytocompatibility of the nanosystems was evaluated using a normal human cell line, namely, bronchial
epithelial cells (16HBE) [35]. 16HBE was chosen because it is one of the ost co monly used model cell
lines for evaluating the cytotoxicity of drugs and toxicants, due to its high sensibility to environ ental
toxicants [36–38]. The studies were carried out in triplicate by incubating the cells for 24 h with empty
and OZ-loaded nanosystems at increasing drug concentrations. The results in terms of cell viability (%)
are reported in Figure 10. The experiments confirmed that no cytotoxic effects were generated by the
empty polymer aggregates showing, in fact, an average cell viability higher than 80%, even at the higher
tested concentration. Moreover, we can observe a high cytocompatibility of both OZ-loaded systems at
50 and 100 µM of loaded drug, compared with that of the pure drug. Although the cytocompatibility
of the free drug is very low and consequently reduces that of the OZ-loaded syste s at 200 and 350
µM, the cell toxicity produced by the latter was attenuated, confirming the possibility of using these
nanosystems for further evaluation in vivo at concentrations below 200 µM of loaded drug.
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Figure 10. Cell viability evaluated by MTS on 16-HBE cells, after 24 h of
incubation with HA-FA-HEG-OA, HA-FA-HEG-SA, HA-FA-HEG-OA-OZ, HA-FA-HEG-SA-OZ,
and olanzapine alone.
4. Conclusions
Over the years, pharmaceutical research always showed a great interest in the use of polymeric
materials as drug carriers, capable of improving biocompatibility and bioavailability. Among these
carriers, polymeric nanoparticles have great potential. In this study, hyaluronan copolymers grafted
with propargylated ferulate fluorophores linked to fatty-acid residues by means of hexa(ethylene glycol)
spacers, HA-FA-HEG-OA and HA-FA-HEG-SA, were properly synthesized, characterized, and tested
as biocompatible polymeric materials, potentially useful as self-assembled colloidal nanosystems for
drug delivery. The obtained nanosystems were characterized from the physico-chemical point of
view in terms of average size, zeta potential, and aggregation capacity in an aqueous environment,
showing an average size around 180–360 nm, a narrow dimensional distribution, and negative surface
charge. The results demonstrated the possibility of using polymeric systems for the production of
nano-aggregates capable of delivering hydrophobic drugs such as OZ (Figure 11). Finally, the results
of the cytotoxicity test confirmed the absence of cytotoxic effects on a normal human cell line, i.e.,
bronchial epithelial cells, at concentrations below 200 µM of loaded drug.
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provide a biocompatible vector for prolonged release of the drug in situ, and it sets the basis for the
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